The Influence of Vitamin D on Mammographic Density: Results from CALGB 70806 (Alliance) a Randomized Clinical Trial.

Autor:	Wood ME; University of Vermont College of Medicine, Burlington, Vermont. Marie.Wood@uvm.edu., Liu H; Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota., Storrick E; Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota., Zahrieh D; Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota., Le-Petross HC; University of Texas MD Anderson Cancer Center, Houston, Texas., Jung SH; Alliance Statistics and Data Center, Duke University, Durham, North Caroline., Zekan P; Southeast Clinical Oncology Research Consortium NCORP, Winston-Salem, North Caroline., Kemeny MM; Queens Cancer Center, Queens Hospital, Jamaica, New York., Charlamb JR; State University of New York Upstate Medical University, Syracuse, New York., Wang LX; Bay Area Tumor Institute NCORP, Oakland, California., Unzeitig GW; Doctor's Hospital of Laredo, Laredo, Texas., Johnson CS; Roswell Park Comprehensive Cancer Center, Buffalo, New York., Garber JE; Dana-Farber/Partners CancerCare, Boston, Massachusetts., Marshall JR; Roswell Park Comprehensive Cancer Center, Buffalo, New York., Bedrosian I; University of Texas MD Anderson Cancer Center, Houston, Texas.
Jazyk:	angličtina
Zdroj:	Cancer prevention research (Philadelphia, Pa.) [Cancer Prev Res (Phila)] 2021 Jul; Vol. 14 (7), pp. 753-762. Date of Electronic Publication: 2021 Apr 13.
DOI:	10.1158/1940-6207.CAPR-20-0581
Abstrakt:	Current therapies for breast cancer prevention only prevent estrogen receptor positive (ER+) disease and toxicity limits use of these agents. Vitamin D is a potential prevention therapy for both ER+ and ER- disease and is safe with few side effects. This study evaluates the effect of 1-year of vitamin D supplementation on mammographic density (MD), a biomarker of breast cancer risk in a multicenter randomized controlled trial. Premenopausal women with ≥25% MD and no history of cancer were randomly assigned to 2,000 international units (IU) of vitamin D or placebo orally daily for 1 year. Change in percent MD was evaluated using Cumulus software after all participants completed treatment. Three hundred women enrolled between January 2011 and December 2013 with a mean age of 43 and diverse ethnicity [14% Hispanic, 12% African American (AA)]. Supplementation significantly increased vitamin D levels compared with placebo (14.5 ng/mL vs. -1.6 ng/mL; P < 0.0001) with all participants on the vitamin D arm achieving vitamin D sufficiency at 12 months. Vitamin D was safe and well tolerated. After adjustment for baseline MD, the mean between-arm difference (vitamin D vs. placebo) at 1 year was -0.75 (-0.26, 1.76; P = 0.56). A greater effect was seen for women with ≥50% MD and AA women, although neither reached significance. This randomized controlled trial demonstrated significant improvement in vitamin D levels with 2,000 IU for 1 year, with 100% of supplemented women achieving sufficiency. However, a null effect was seen regarding change in MD for premenopausal women (the primary outcome of the study). PREVENTION RELEVANCE: Current therapies for breast cancer prevention only prevent estrogen receptor positive (ER+) disease and are underutilized due to toxicity and side effects. Vitamin D is a potential prevention therapy for both ER+ and ER- disease and is safe with few side effects. (©2021 American Association for Cancer Research.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu